Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TTY Biopharm CoROCO:4105 85 Receivables Turnover is 1.22 as of Jun. 2026. GuruFocus rates ROCO:4105 with a GF Score™ of 85/100 and a GF Value™ of NT$88.23 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 947 Drug Manufacturers companies, TTY Biopharm Co ranks worse than 55.44% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. TTY Biopharm Co's Revenue for the
three
months ended in Jun. 2026 was NT$1,652 Mil. TTY Biopharm Co's average Accounts Receivable for the
three
months ended in Jun. 2026 was NT$1,351 Mil.
Hence, TTY Biopharm Co's Receivables Turnover for the
three
months ended in Jun. 2026 was 1.22.
TTY Biopharm Co (ROCO:4105) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
TTY Biopharm Co Receivables Turnover Related Terms
TTY Biopharm Co Receivables Turnover Historical Data
* Premium members only.
The historical data trend for TTY Biopharm Co's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, TTY Biopharm Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TTY Biopharm Co Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TTY Biopharm Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where TTY Biopharm Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TTY Biopharm Co (ROCO:4105) has a Receivables Turnover of 1.22 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on TTY Biopharm Co and its competitors. According to the industry distribution chart, TTY Biopharm Co ranks #525 out of 947 companies in the Drug Manufacturers industry, placing it in the top 55.4%.
Is TTY Biopharm Co's Receivables Turnover too high?
TTY Biopharm Co's current Receivables Turnover is 1.22. The Drug Manufacturers industry median Receivables Turnover is 5.07. TTY Biopharm Co's value of 1.22 is 75.9% below this industry median. Based on the distribution chart, TTY Biopharm Co ranks #525 out of 947 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, TTY Biopharm Co has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TTY Biopharm Co's Receivables Turnover compare to ZTS?
According to the Drug Manufacturers industry distribution chart, TTY Biopharm Co ranks #525 out of 947 companies for Receivables Turnover. This places TTY Biopharm Co in the lower half of its industry. The industry median Receivables Turnover is 5.07. TTY Biopharm Co's value of 1.22 is 75.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TTY Biopharm Co's current Receivables Turnover of 1.22 is 75.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on TTY Biopharm Co and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TTY Biopharm Co's current Receivables Turnover is 1.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TTY Biopharm Co stock overvalued right now?
Based on GuruFocus' analysis, TTY Biopharm Co (ROCO:4105) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$88.23, compared to a current price of NT$76.10 — trading 13.7% below its estimated fair value. The current Receivables Turnover is 1.22 and 75.9% below the Drug Manufacturers industry median of 5.07. TTY Biopharm Co's overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For TTY Biopharm Co (ROCO:4105), the current Receivables Turnover is 1.22 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TTY Biopharm Co (ROCO:4105) Overvalued in 2026?
Based on GuruFocus' analysis, TTY Biopharm Co stock appears to be undervalued.
The current stock price of NT$76.10 is trading 13.7% below its estimated GF Value™ of NT$88.23.
GuruFocus considers TTY Biopharm Co to be Modestly Undervalued.
Key valuation signals for ROCO:4105:
Receivables Turnover: 1.22
GF Value™: NT$88.23 vs. price of NT$76.10 (13.7% below fair value)
Industry Position: 75.9% below the Drug Manufacturers median (#525 of 947)
No single metric tells the full story. See the ROCO:4105 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TTY Biopharm Co Ltd is engaged in the manufacturing and marketing of pharmaceuticals and chemical drugs. The company's operating segments includes Oncology Business unit, Health Care Business unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business unit segment. It generates maximum revenue from the Oncology segment. Geographically, it derives a majority of revenue from Taiwan and also has a presence in America. Some of its products include Algitab, Alginos, Sulfin, Metacin, Cepiro, Brosym, Colimycin, Cubicin, and others.
85GF Score
Get the complete analysis for ROCO:4105
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4105 has been successfully added to your 
